Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome [Yahoo! Finance]
X4 Pharmaceuticals, Inc. (XFOR)
Last x4 pharmaceuticals, inc. earnings: 3/12 07:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
decision expected from the European Commission in Q2 2026 Partnership with X4 Pharmaceuticals for Norgine-led commercialisation in Europe AMSTERDAM Feb. 27, 2026 /PRNewswire/ -- Norgine B.V., a leading European specialty pharmaceutical company, today welcomes the positive opinion issued by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the granting of a marketing authorisation under exceptional circumstances[*] for XOLREMDI ® (mavorixafor) in patients aged 12 years and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.[1] Norgine Logo (PRNewsfoto/Norgine Pharmaceuticals Limited) This CHMP positive opinion is an important regulatory milestone for patients living with WHIM syndrome for whom there is currently no other licensed treatment option.[2] The condition results from dysfunction of the chemokin
Show less
Read more
Impact Snapshot
Event Time:
XFOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XFOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XFOR alerts
High impacting X4 Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
XFOR
News
- X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare ConferenceGlobeNewswire
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome [Yahoo! Finance]Yahoo! Finance
- X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM SyndromeGlobeNewswire
XFOR
Earnings
- 5/1/25 - Beat
XFOR
Analyst Actions
- 12/5/25 - Stifel
XFOR
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- XFOR's page on the SEC website